tiprankstipranks
Trending News
More News >
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Hong Kong Market
Advertisement

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Financial Statements

Compare
1 Followers

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Overview

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H's market cap is currently HK$20.40B. The company's EPS TTM is HK$0.114; its P/E ratio is 13.92; and it has a dividend yield of 0.89%. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is scheduled to report earnings on April 25, 2025, and the estimated EPS forecast is HK$0.02. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 5.28B¥ 5.45B¥ 7.16B¥ 6.37B¥ 5.33B
Gross Profit¥ 1.76B¥ 1.80B¥ 2.33B¥ 2.03B¥ 2.09B
Operating Income¥ 741.31M¥ -238.11M¥ 1.14B¥ 773.20M¥ 1.33B
EBITDA¥ 1.20B-¥ 1.37B¥ 726.64M¥ 1.88B
Net Income¥ 646.74M-¥ 727.43M¥ 240.79M¥ 1.02B
Balance Sheet
Cash & Short-Term Investments¥ 2.56B¥ 2.27B¥ 3.45B¥ 3.93B¥ 3.54B
Total Assets¥ 17.34B¥ 19.20B¥ 20.81B¥ 19.11B¥ 19.03B
Total Debt¥ 2.98B¥ 3.78B¥ 6.46B¥ 5.65B¥ 5.65B
Net Debt¥ 1.29B¥ 1.93B¥ 4.33B¥ 2.71B¥ 2.93B
Total Liabilities¥ 5.14B¥ 7.22B¥ 8.41B¥ 7.58B¥ 7.34B
Stockholders' Equity¥ 12.15B¥ 11.91B¥ 12.31B¥ 11.41B¥ 11.57B
Cash Flow
Free Cash Flow¥ 1.99B----
Operating Cash Flow¥ 2.19B¥ 398.22M--¥ 37.28M
Investing Cash Flow-¥ 1.22B¥ 249.84M¥ 719.93M-
Financing Cash Flow--¥ 329.56M-¥ 2.51B
Currency in CNY

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Earnings and Revenue History

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Debt to Assets

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Cash Flow

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis